| diabetes type 2 | versus No demonstrated result for efficacy | 9 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Seino, 2011 | alogliptin vs | | | | | Seino, 2011 | alogliptin vs | | | | | Bosi , 2011 | alogliptin vs | | | | | Kaku, 2011 | alogliptin vs | | | | | Rosenstock, 2010 | alogliptin vs | | | | | Rosenstock, 2009 | alogliptin vs | | | | | Pratley, 2009 | alogliptin vs | | | | | Pratley, 2009 | alogliptin vs | | | | | DeFronzo , 2008 | alogliptin vs | | | |
| Trial | Treatments | Patients | Method |
|---|
| Seino, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Seino, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Bosi , 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Kaku, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Rosenstock, 2010 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Rosenstock, 2009 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Pratley, 2009 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Pratley, 2009 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | DeFronzo , 2008 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
| diabetes type 2 | versus placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| EXAMINE, 2013 | alogliptin vs placebo | | | all causes death 0.88 [0.71; 1.09] CVdeath 0.85 [0.66; 1.10] CV events 0.96 [0.83; 1.11] |
| Trial | Treatments | Patients | Method |
|---|
| EXAMINE, 2013 | alogliptin (n=2701) vs. placebo (n=2679) | patients with type 2 diabetes and either an acute myocardial
infarction or unstable angina requiring hospitalization within the previous 15
to 90 days | double-blind Parallel groups Sample size: 2701/2679 Primary endpoint: death from cardiovascular causes, nonfatal myocardial FU duration: 1.5 years (median) |
|
| diabetes type 2 | versus placebo or control No demonstrated result for efficacy alogliptin inferior to placebo (add on MET) in terms of HbA1c goal <7% in Nauck, 2009 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Nauck, 2009 | alogliptin vs placebo (add on MET) | | HbA1c goal <7% 2.40 [1.55; 3.70] | all hypoglycemia 0.00 [0.00; NaN] | | EXAMINE, 2011 | alogliptin vs placebo | | | all cause deaths 0.88 [0.71; 1.08] CV deaths 0.80 [0.60; 1.05] stroke 0.90 [0.55; 1.48] MI 1.07 [0.88; 1.31] CV events 0.96 [0.83; 1.11] |
| Trial | Treatments | Patients | Method |
|---|
| Nauck, 2009 | alogliptin 12.5 and 25 mg once daily (n=210) vs. placebo (n=104) | patients whose HbA(1c) levels were inadequately controlled on metformin alone | double-blind Parallel groups Sample size: 210/104 Primary endpoint: FU duration: 26 weeks | | EXAMINE, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
